Clinical Trial Update: Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial assessing deutetrabenazine (TEV-50717) for reducing tics in children and adolescents with Tourette Syndrome has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tourette Syndrome

Drugs mentioned

• deutetrabenazine (deutetrabenazine)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Tourette Syndrome | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-06-04